6533b7d3fe1ef96bd1260ac7
RESEARCH PRODUCT
Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Comparative Study
Sebastiano MercadanteClaudio AdileCasuccio AlessandraAndrea CostanziFederica Aiellisubject
Malefentanyl pectin nasal spraymedicine.medical_treatmentAdministration OralContext (language use)Fentanyl03 medical and health sciences0302 clinical medicinemedicineHumansCancer painGeneral NursingNursing (all)2901 Nursing (miscellaneous)Pain MeasurementAnalgesicsCross-Over StudiesMorphinebusiness.industryNasal SpraysMiddle Agedbreakthrough painCrossover studyFentanylRegimenTreatment OutcomeAnesthesiology and Pain MedicineOpioidNasal sprayoral morphine030220 oncology & carcinogenesisAnesthesiaMorphinePectinsFemaleNeurology (clinical)businessCancer painbreakthrough pain; Cancer pain; fentanyl pectin nasal spray; oral morphine; Nursing (all)2901 Nursing (miscellaneous); Neurology (clinical); Anesthesiology and Pain Medicine030217 neurology & neurosurgerymedicine.drugdescription
Context Fentanyl products have shown superiority over oral opioids for the management of breakthrough cancer pain (BTcP). However, these studies did not use an appropriate patient selection, and drugs have been compared using a different rationale. Objectives The aim of this randomized, crossover, controlled study was to compare the efficacy and safety of fentanyl pectin nasal spray (FPNS) and oral morphine (OM), given in doses proportional to opioid daily doses. Methods Cancer patients with pain receiving â¥60 mg of OM equivalents/day and presenting with â¤3 episodes of BTcP/day were included. Patients received, in a randomized, crossover manner, FPNS or OM at doses proportional to the daily opioid regimen in four consecutive episodes of BTcP. Pain intensity was measured before (T0), 15 (T15), and 30 minutes (T30) after study drugs. Results A total of 167 episodes were treated, 82 with FNPS and 85 with OM. A statistical difference in pain intensity between the two groups was observed at T15, but not at T30 (P = 0.018 and P = 0.204, respectively). In a greater number of episodes treated with FPNS, there was a pain decrease of â¥33% in comparison with OM after 15 and 30 minutes (76.5% vs. 32.8%, and 89% vs. 54.9%, respectively). Similar differences were found in the decrease in pain intensity of â¥50% after 15 and 30 minutes (52.3% vs. 11.4%, and 75% vs. 45.8%, respectively). The difference was highly significant at T15 (P < 0.0005). The mean (SD) pain difference at T15 of FPNS and OM were 3.24 (1.7) and 2.70 (1.2), respectively, whereas the mean (SD) SPIDs30 of FPNS and OM were 4.87 (1.7) and 4.54 (1.5), respectively. The difference was highly significant at T15 (P = 0.019). No severe adverse effects after study drug administration were observed. Conclusion When used in doses proportional to the basal opioid regimen, FPNS showed a superior analgesic effect over OM for the management of BTcP. Only minor adverse effects were found with both medications.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2016-01-01 |